chronic plaque psoriasis

Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis

harminka — Mon, 04 Feb 2008 08:27:08 -0600

One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year.

Ustekinumab significantly improves psoriasis

harminka — Thu, 04 Oct 2007 06:08:59 -0500

The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).

Remicade therapy productive in patients treated for chronic plaque psoriasis

harminka — Fri, 02 Feb 2007 13:32:35 -0600